Philips Healthcare (a division of Royal Philips Electronics NV), as part of a new bid to connect the dots between its own product offerings, acquired InnerCool Therapies Inc., maker of surface and endovascular cooling devices for the management of cardiac patients. [See Deal] Philips paid $12.75 million to Taxus Cardium Pharmaceuticals Group Inc., netting the company a 100% return after it bought InnerCool for $6 million three years ago. The payment gives Cardium, a cardiac tissue engineering company that saw InnerCool’s commercial-ready property as a counter to its early-stage pipeline, some much needed cash while giving Philips a nice fit for its own cardiac resuscitation business.
Mike Miller, senior vice president of the Philips Cardiac Care division, says InnerCool fits into the company’s broader "care cycle"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?